Peterson Wealth Services Has $1.95 Million Stake in DexCom, Inc. $DXCM

Peterson Wealth Services lifted its stake in DexCom, Inc. (NASDAQ:DXCM) by 423.6% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 28,937 shares of the medical device company’s stock after purchasing an additional 23,410 shares during the quarter. Peterson Wealth Services’ holdings in DexCom were worth $1,947,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in DXCM. Andra AP fonden purchased a new stake in DexCom in the 2nd quarter worth approximately $26,000. Twin Peaks Wealth Advisors LLC purchased a new position in shares of DexCom during the 2nd quarter valued at $26,000. SJS Investment Consulting Inc. increased its stake in shares of DexCom by 4,800.0% in the third quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock worth $26,000 after acquiring an additional 384 shares during the last quarter. Financial Consulate Inc. purchased a new stake in shares of DexCom during the third quarter worth $29,000. Finally, Sound Income Strategies LLC raised its holdings in shares of DexCom by 83.8% during the third quarter. Sound Income Strategies LLC now owns 625 shares of the medical device company’s stock worth $43,000 after acquiring an additional 285 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Richard Alexander Collins sold 3,948 shares of DexCom stock in a transaction on Monday, November 10th. The shares were sold at an average price of $55.17, for a total value of $217,811.16. Following the transaction, the director owned 37,994 shares in the company, valued at $2,096,128.98. This trade represents a 9.41% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Jacob Steven Leach bought 18,200 shares of the business’s stock in a transaction on Monday, November 10th. The shares were purchased at an average cost of $55.04 per share, with a total value of $1,001,728.00. Following the transaction, the chief operating officer owned 331,697 shares in the company, valued at approximately $18,256,602.88. The trade was a 5.81% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have sold a total of 7,866 shares of company stock valued at $448,177 over the last 90 days. 0.32% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts have commented on DXCM shares. Canaccord Genuity Group set a $99.00 target price on DexCom and gave the company a “buy” rating in a research note on Friday, October 31st. UBS Group reduced their price target on DexCom from $106.00 to $95.00 and set a “buy” rating for the company in a report on Monday, November 3rd. Sanford C. Bernstein reissued an “outperform” rating and issued a $86.00 price target (up previously from $84.00) on shares of DexCom in a research note on Friday, January 9th. Robert W. Baird set a $82.00 price objective on shares of DexCom in a research report on Friday, October 31st. Finally, Argus reduced their target price on shares of DexCom from $100.00 to $90.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $85.00.

DexCom Stock Down 0.7%

Shares of DXCM stock opened at $72.53 on Tuesday. The stock’s 50 day simple moving average is $68.02 and its 200 day simple moving average is $70.59. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $93.25. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.38 and a current ratio of 1.56. The company has a market capitalization of $28.29 billion, a price-to-earnings ratio of 40.29, a PEG ratio of 1.31 and a beta of 1.49.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.